Cart
sales@molnova.com
AG-13958
CAS No. 319460-94-1
AG-13958( AG-013958 )
Catalog No. M20778 CAS No. 319460-94-1
AG-13958 (AG-013958) a potent VEGFR tyrosine kinase inhibitor for the treatment of age-related macular degeneration.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 275 | In Stock |
|
| 5MG | 264 | In Stock |
|
| 10MG | 407 | In Stock |
|
| 25MG | 655 | In Stock |
|
| 50MG | 923 | In Stock |
|
| 100MG | 1228 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAG-13958
-
NoteResearch use only, not for human use.
-
Brief DescriptionAG-13958 (AG-013958) a potent VEGFR tyrosine kinase inhibitor for the treatment of age-related macular degeneration.
-
DescriptionAG-13958 (AG-013958) a potent VEGFR tyrosine kinase inhibitor for the treatment of age-related macular degeneration.
-
In Vitro——
-
In Vivo——
-
SynonymsAG-013958
-
PathwayAngiogenesis
-
TargetVEGFR
-
RecptorVEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number319460-94-1
-
Formula Weight467.5
-
Molecular FormulaC26H22FN7O
-
Purity>98% (HPLC)
-
SolubilityDMSO:5 mg/mL (10.70 mM)
-
SMILESCc1cc(C(=O)Nc2cc(Nc3ccc4c(/C=C/c5ccccn5)n[nH]c4c3)ccc2F)n(C)n1
-
Chemical NameN-[2-Fluoro-5-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]amino]phenyl]-13-dimethyl-1H-pyrazole-5-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Barakat M R Kaiser P . VEGF inhibitors for the treatment of neovascular age-related macular degeneration[J]. Expert Opinion on Investigational Drugs 2009 18(5):637-646.
molnova catalog
related products
-
Motesanib diphosphat...
A potent, orally bioavailable, multikinase inhibitor inhibitor of VEGFR1/2/3, PDGFR and c-Kit with IC50 of 2-6 nM, 84 nM and 8 nM, respectively.
-
VEGFR-2-IN-9
VEGFR-2-IN-9 (KDR-in-4) is a potent KDR/VEGFR2 inhibitor with an IC50 of 7 nM, suitable for breast cancer research.
-
Parsatuzumab
Parsatuzumab (RG 7414) is a humanized monoclonal antibody targeting EGFL7, which is also used as an immunomodulator.
